European Commission Approves Filsuvez(R) for the treatment of Dystrophic and Junctional EB

European Commission Approves Filsuvez for the treatment of Dystrophic and Junctional EB Filsuvez will be the first and only approved treatment for EB Patients DUBLIN, Ireland, and Boston MA, June 23, 2022, Amryt (Nasdaq: AMYT)

https://www.globenewswire.com/news-release/2022/06/23/2467833/0/en/European-Commission-Approves-Filsuvez-for-the-treatment-of-Dystrophic-and-Junctional-EB.html